DRNA News and Press, Dicerna Pharmaceuticals Inc. From 11/18/21

Gainers: Longeveron (NASDAQ:LGVN) +137%. Virtuoso (NASDAQ:VOSOU) +89%. Dicerna (NASDAQ:DRNA) +79%. ClearSign (NASDAQ:CLIR) +33%. Alpine (NASDAQ:ALPP) +22%. Macy's (NYSE:M) +21%. Enthusiast Gaming Holdings (NASDAQ:EGLX) +20%. BJ's (NYSE:BJ) +19%. Jowell Global (NASDAQ:JWEL) +17%. Yatsen Holdin...

The offer made by Novo Nordisk (NYSE:NVO) to acquire Dicerna Pharmaceuticals (DRNA +79.1%), a company advancing ribonucleic acid interference (RNAi)-based drugs, has propelled other biotechs focused on treatments based on the technology. Novo (NVO) is on track to pay as much as 80% premium to...

Shares of Dicerna Pharmaceuticals (NASDAQ: DRNA) , a clinical-stage biopharmaceutical company, are exploding higher today in response to a buyout offer from Novo Nordisk (NYSE: NVO) . Dicerna stock was up 78.6% as of 11 a.m. ET on Thursday. Today, Novo Nordisk agreed to ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Portillo’s (NASDAQ: PTLO ) stock isn’t doing so hot on Thursday and we’re breaking down what has investors in the fast-food chain upset. Source: TonelsonProductions / Shutterstock.com Let&...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Several electric vehicle (EV) stocks are down today and we’re taking a look at why that’s happening. Source: Sopotnicki / Shutterstock.com To start off with, I’ve got to point out that several E...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dicerna Pharmaceuticals (NASDAQ: DRNA ) stock is surging higher on Thursday following news of a massive deal with Novo Nordisk . Source: Shutterstock The deal will have Novo Nordisk acquiring Dicerna Pharma...

– Acquisition to Accelerate and Expand Novo Nordisk Development of RNAi Therapeutics Using Dicerna’s Proprietary GalXC™ Technology Platform – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive ag...

– Milestone Triggers Two Single-Digit Multimillion-Dollar Payments to Dicerna – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Eli Lilly and Compan...

– Belcesiran Was Shown to Be Safe and Well Tolerated in Phase 1 Trial and Demonstrated Robust, Dose-Dependent Reductions in Serum Alpha-1 Antitrypsin – – Enrollment in ESTRELLA Phase 2 Study of Belcesiran Is Ongoing; Global Rollout to Additional Trial ...

Image source: The Motley Fool. Dicerna Pharmaceuticals, Inc (NASDAQ: DRNA) Q3 2021 Earnings Call Nov 9, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Dicerna Pharmaceuticals, Inc (DRNA) Q3 2021 Earnings Call Trans...